本文選題：回生口服液　切入點(diǎn)：非小細(xì)胞肺癌　出處：《安徽醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:回生口服液由多種中藥組份提煉而成,具有多種功效,藥物副反應(yīng)較少,臨床上常作為腫瘤綜合治療種的輔助治療手段,回生口服液中所含有的活血化瘀成分,可改善患者血凝狀態(tài),提高腫瘤組織的血供,起到增強(qiáng)放化療療效的作用。另有文獻(xiàn)報道,回生口服液還可提高患者生活質(zhì)量,減輕放化療毒副反應(yīng)[1-2],據(jù)此,本試驗將探討回生口服液聯(lián)合同步放化療治療局部晚期NSCLC的療效。方法:篩選2014年12月至2016年10月于我科治療的局部晚期無手術(shù)指征的NSCLC患者68例,經(jīng)纖支鏡、肺穿或胸水脫落細(xì)胞學(xué)檢查,細(xì)胞學(xué)或病理學(xué)明確診斷,且為首次確診。通過隨機(jī)方法分成兩組,其中對照組34例,男20例,女14例;腺癌13例,鱗癌21例。實驗組34例,男18例,女16例;腺癌15例,鱗癌19例。試驗組患者給予同步放化療和回生口服液,回生口服液由成都地奧集團(tuán)天府藥業(yè)股份有限公司生產(chǎn)。藥品規(guī)格與性狀:棕褐色液體;特臭,味苦、辛,10ml/支�；厣诜鹤苑暖熎鹑帐褂�10 m L/次,3次/d,持續(xù)至放療結(jié)束。而對照組單純行放化療。其中放療采用6 MV-X三維適形放療,2Gy/次,每周5次�？偭�60~70Gy。化療皆采用包含鉑類的一線化療方案,并根據(jù)患者一般狀況及臨床實際,選擇GP(順鉑+吉西他濱)、PP(順鉑+培美曲賽)、TP(順鉑+紫杉醇類)[3]。嚴(yán)格按照體表面積計算給藥劑量,化療期間常規(guī)予以止吐、抑酸、水化等對癥處理。治療過程中評價毒副反應(yīng),治療至后程評價客觀療效。所有患者治療前及治療后程檢測血漿凝血酶原時間、活化部分凝血酶原時間、D-二聚體、纖維蛋白(Fib)。結(jié)果:實驗組客觀反應(yīng)率高于對照組(P0.05);對照組治療前后各項凝血指標(biāo)水平無統(tǒng)計學(xué)差異,實驗組治療后Fib水平低于對照組(P0.05);對照組不良反應(yīng)、急性放射性損傷發(fā)生率均高于實驗組。結(jié)論:采用回生口服液聯(lián)合同步放化療,可提高腫瘤近期療效、改善患者凝血功能,降低放化療不良反應(yīng)發(fā)生率,提高患者生活質(zhì)量,使患者治療中的順應(yīng)性增加,以確保臨床治療計劃按時定量完成。
[Abstract]:Objective: Huisheng oral liquid was extracted from a variety of traditional Chinese medicine components. It has many functions and few side effects. It is often used in clinic as an auxiliary treatment method for comprehensive treatment of tumor. The Huisheng oral liquid contains the components of promoting blood circulation and removing blood stasis. It can improve the state of hemagglutination, increase the blood supply of tumor tissue and enhance the curative effect of radiotherapy and chemotherapy. According to other literature, Huisheng oral liquid can also improve the quality of life of patients and alleviate the side effects of radiotherapy and chemotherapy [1-2]. The purpose of this study was to investigate the efficacy of Huisheng oral liquid combined with concurrent radiotherapy and chemotherapy in the treatment of local advanced NSCLC. Methods: 68 patients with locally advanced NSCLC who were treated in our department from December 2014 to October 2016 were selected and treated with fiberoptic bronchoscopy. Cytological examination of exfoliation of lung or pleural effusion, cytological or pathological diagnosis was confirmed for the first time. It was randomly divided into two groups: control group (n = 34), male (n = 20), female (n = 14), adenocarcinoma (n = 13), squamous cell carcinoma (n = 21) and experimental group (n = 34). There were 18 males and 16 females, 15 adenocarcinoma and 19 squamous cell carcinomas. The patients in the experimental group were given concurrent radiotherapy and chemotherapy and Huisheng oral liquid, which was produced by Chengdu Diao Group Tianfu Pharmaceutical Co., Ltd. Hisheng oral liquid was used 10 mL / d from the day of radiotherapy and lasted until the end of radiotherapy. The control group was treated with radiotherapy alone, in which 6 MV-X three-dimensional conformal radiotherapy was used for 2 Gy / time. Five times a week. The total amount of chemotherapy was 60,70Gy.All patients were treated with first-line chemotherapy regimen containing platinum, and according to the patients' general condition and clinical practice, GP( cisplatin gemcitabine) PPp (cisplatin pemetrexide) [3]. The dosage was calculated strictly according to the body surface area. During chemotherapy, the drug was routinely treated with antiemetic, acid suppression, hydration and other symptomatic treatments. The side effects were evaluated during the treatment. Objective curative effect was evaluated after treatment. Plasma prothrombin time and activated partial prothrombin time were measured before and after treatment in all patients. Results: the objective reaction rate in the experimental group was higher than that in the control group (P 0.05), the coagulation index level in the control group was not significantly different before and after treatment, the Fib level in the experimental group was lower than that in the control group after treatment (P 0.05), the adverse reaction in the control group was lower than that in the control group. Conclusion: Huisheng oral liquid combined with concurrent radiotherapy and chemotherapy can improve the short-term curative effect of tumor, improve the coagulation function of patients, reduce the incidence of adverse reactions of radiotherapy and chemotherapy, and improve the quality of life of the patients. Increase patient compliance in treatment to ensure timely and quantitative completion of clinical treatment plans.
【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R734.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 石遠(yuǎn)凱;孫燕;于金明;丁翠敏;王子平;王長利;王東;王存德;王征;王孟昭;支修益;盧鈾;馮繼鋒;劉云鵬;劉曉晴;劉巍;伍鋼;李小梅;李凱;李恩孝;李薇;陳公琰;陳正堂;余萍;吳寧;吳密璐;肖文華;張力;張沂平;張樹才;楊樹軍;宋霞;林冬梅;羅榮城;單莉;周彩存;周宗玫;趙瓊;胡成平;胡毅;郭其森;常建華;黃誠;曾tD;韓寶惠;韓曉紅;郟博;韓穎;黃昱;;中國晚期原發(fā)性肺癌診治專家共識(2016年版)[J];中國肺癌雜志;2016年01期

2 賀家勇;王國良;張華彬;楊晨晨;;惡性腫瘤患者凝血功能相關(guān)指標(biāo)與其臨床特征關(guān)系的研究[J];國際檢驗醫(yī)學(xué)雜志;2015年17期

3 韓正祥;孫旋;魏艷紅;李艷;錢龍娣;;回生口服液改善癌癥患者圍化療期便秘臨床療效研究[J];徐州醫(yī)學(xué)院學(xué)報;2015年02期

4 魏亞寧;段敏丹;賈友超;臧愛民;;回生口服液治療晚期非小細(xì)胞肺癌的療效及對TGF-β,-α表達(dá)的影響[J];中國老年學(xué)雜志;2014年21期

5 賈友超;臧愛民;宋會穎;魏亞寧;霍燃;楊陽;;回生口服液聯(lián)合順鉑方案化療對肺癌患者免疫功能影響分析[J];中國醫(yī)學(xué)前沿雜志(電子版);2014年11期

6 曾柏榮;文靜;;中醫(yī)藥提高腫瘤患者生活質(zhì)量的研究概況[J];湖南中醫(yī)雜志;2014年10期

7 仝自強(qiáng);;肺癌放射治療的研究進(jìn)展[J];中國衛(wèi)生產(chǎn)業(yè);2014年24期

8 楊文娟;王良花;陸瓊;周雪明;;回生口服液輔助放療治療惡性腫瘤骨轉(zhuǎn)移的療效觀察[J];山東醫(yī)藥;2014年31期

9 肖樺;李羅翔;秦旭華;賴?yán)?;回生口服液調(diào)控Wnt通路CyclinD1影響人肺腺癌細(xì)胞增殖的機(jī)制[J];成都中醫(yī)藥大學(xué)學(xué)報;2014年02期

10 劉朝敏;姜鶴群;徐可;周艷剛;劉薇;;回生口服液聯(lián)合鹽酸羥考酮緩釋片治療癌性疼痛的療效[J];中國老年學(xué)雜志;2014年11期

，

本文編號：1683316